Expert forum

Principles of diagnosis and treatment of respiratory comorbidities:an example of comorbidities of chronic obstructive pulmonary disease

  • SHI Guochao ,
  • NI Yingmeng
Expand
  • Department of Respiratory and Critical Care Medicine; Institute of Respiratory Diseases,Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Emergency Prevention & Control and Diagnosis & Treatment of Respiratory Infectious Diseases; Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2026-07-01

  Revised date: 2026-07-21

  Accepted date: 2026-07-22

  Online published: 2026-08-31

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic airway diseases and frequently coexists with multiple comorbidities such as cardiovascular diseases and lung cancer, substantially increasing disease burden, diagnostic and therapeutic complexity, and mortality risk. Taking COPD comorbidities as an example, this article systematically reviews the principles of diagnosis and treatment for respiratory comorbidities based on the 2026 report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), as well as the latest domestic and international consensus statements and evidence-based findings. It focuses on COPD complicated by lung cancer and cardiovascular di-seases. The presence of comorbidities may lead to symptom overlap (e.g., dyspnea) and consequently increase missed diagnosis and misdiagnosis rates, while also causing issues such as polypharmacy-related conflicts and restricted treatment options. At the diagnostic level, this article proposes a two‑tier screening strategy based on symptom similarity (e.g., mismatch between symptom severity and objective findings) and shared risk factors/pathogenic mechanisms (e.g., smoking, chronic inflammation), emphasizing early coordinated screening through an approach of "one test, multiple uses." At the therapeutic level, a patient‑centered integrated care model is advocated, encompassing strategies such as concurrent management of comorbidities, prioritization of critical issues, benefit-risk balance, optimization of non‑pharmacological therapies, regular dynamic assessment, multidisciplinary collaboration, and artificial intelligence empowerment, aiming to achieve therapeutic targets for both COPD and its comorbidities. Effective management of COPD comorbidities requires clinicians to develop awareness of comorbidities, overcome disciplinary barriers, and rely on standardized screening pathways, high‑quality evidence, and intelligent decision‑support tools to build a comprehensive care system covering "early screening, concurrent treatment, and full-course management," ultimately improving long‑term outcomes and quality of life for patients.

Cite this article

SHI Guochao , NI Yingmeng . Principles of diagnosis and treatment of respiratory comorbidities:an example of comorbidities of chronic obstructive pulmonary disease[J]. Journal of Diagnostics Concepts & Practice, 2026 , 25(04) : 406 -412 . DOI: 10.16150/j.1671-2870.2026.04.003

References

[1] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2026 report)[R/OL]. [2026-07-01]. http://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf.
[2] Zhao G, Wang L, Lei S, et al. All-cause and cause-specific mortality in chronic obstructive pulmonary di-sease: A systematic review and meta-analysis[J]. Int J Chronic Obstr Pulm Dis, 2025, 20:4173-4190.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 《慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识》撰写组. 慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识[J]. 中华结核和呼吸杂志, 2022, 45(12):1180-1191.
  Expert Group of the Chronic Obstructive Pulmonary Disease Assembly; Chinese Thoracic Society, Chinese Medical Association. Chinese expert consensus on the management of cardiovascular comorbidities in patients with chronic obstructive pulmonary disease[J]. Chin J Tuberc Respir Dis, 2022, 45(12):1180-1191.
[4] 中国老年医学学会心电与心功能分会, 中华医学会呼吸病学分会慢阻肺病学组, 苏州工业园区东方华夏心血管健康研究院. 心力衰竭合并慢性阻塞性肺疾病的多学科管理专家共识[J]. 中华内科杂志, 2025, 64(11):1065-1083.
  Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics; Chronic Obstructive Pulmonary Disease Group; Chinese Thoracic Society. Expert consensus on the multidisciplinary management of patients with heart failure and chronic obstructive pulmonary disease[J]. Chin J Intern Med, 2025, 64(11):1065-1083.
[5] Zhou C, Qin Y, Zhao W, et al. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease[J]. Transl Lung Cancer Res, 2023, 12(8):1661-1701.
[6] Xue R, Liu C, Yu Q, et al. Appraisal of β-blocker use in patients with cardiovascular disease and chronic obstructive pulmonary disease[J]. Am J Cardiovasc Drugs, 2025, 25(5):577-592.
[7] He Y, Liu B, Li W, et al. COPD-lung cancer comorbidity: Mechanistic insights and precision oncology implications[J]. Int J Chronic Obstr Pulm Dis, 2026, 21:1-16.
[8] Marel M, Domecky P, Fernando CML, et al. History of chronic obstructive pulmonary disease may contribute to earlier diagnosis of lung cancer[J]. Vivo, 2026, 40(2):1153-1162.
[9] Shrikrishna D, Steer J, Bostock B, et al. Chronic obstructive pulmonary disease and the management of cardiopulmonary risk in the UK: A systematic literature review and modified Delphi study[J]. Int J Chronic Obstr Pulm Dis, 2025, 20:2073-2090.
[10] 中华医学会呼吸病学分会. 早期肺癌诊断中国专家共识(2023年版)[J]. 中华结核和呼吸杂志, 2023, 46(1):1-18.
  Chinese Thoracic Society. Chinese expert consensus on diagnosis of early lung cancer (2023 Edition)[J]. Chin J Tuberc Respir Dis, 2023, 46(1):1-18.
[11] de Simón Gutiérrez R, Navarrete B A, Alonso Ortiz M B, et al. Integrated care for COPD and cardiovascular comorbidities: A multidisciplinary approach for the cardiopulmonary patient[J]. Med De Fam SEMERGEN, 2026, 52(2):102678.
[12] Guan X, Xia Y, Ai J, et al. Effects of integrated care on patients with COPD and comorbidities: A systematic review[J]. Ther Adv Respir Dis, 2026, 20:17534666251414315.
[13] Chen L, Song D, Hou S, et al. The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis[J]. Front Immunol, 2025, 16:1627557.
Outlines

/

〈 〉